PMID- 10404083
OWN - NLM
STAT- MEDLINE
DCOM- 19990824
LR  - 20190708
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 84
IP  - 4
DP  - 1999 Aug 20
TI  - DNA amplification on chromosome 6p12 in non small cell lung cancer detected by 
      arbitrarily primed polymerase chain reaction.
PG  - 344-9
AB  - Gene amplification is clearly an important aspect of tumour growth and 
      development and has prognostic significance in certain tumours. The 
      identification and genetic characterisation of new areas of amplification in 
      human malignancy remains an important goal in understanding the underlying 
      genetic lesions within these tissues. In the present work, arbitrarily primed-PCR 
      (AP-PCR) has been applied to detect and characterise amplified DNA fragments in 
      human non small cell lung cancer (NSCLC). Our results show that gains of genomic 
      sequences occur at high frequency (64% of all genomic changes analysed). 
      Moreover, we succeeded in detecting a genomic sequence that is highly amplified 
      in one of the tumours analysed. The amplification intensity of this DNA fragment 
      was also increased in 29 (45%) of the 65 NSCLC patients from our study. The 
      amplified DNA fragment was isolated and identified as a 600 bp sequence mapped to 
      chromosome 6p12. This sequence did not show significant homology with known human 
      DNA sequences. Interestingly, a gene related to cancer processes, the pim-1 
      oncogene, is placed neighbouring to this region on chromosome 6. Survival studies 
      revealed that disease-free interval of NSCLC patients was shorter in patients 
      bearing the amplified sequence (p = 0.05 by the Breslow test). Our findings 
      suggest that the amplified sequence located on chromosome 6 might be relevant in 
      the pathogenesis of human NSCLC. Int. J. Cancer (Pred. Oncol.), 84:344-349, 1999.
CI  - Copyright 1999 Wiley-Liss, Inc.
FAU - De Juan, C
AU  - De Juan C
AD  - Departamento de Bioquimica y Biologia Molecular, Facultad de Farmacia, 
      Universidad Complutense de Madrid, Madrid, Spain.
FAU - Iniesta, P
AU  - Iniesta P
FAU - Cruces, J
AU  - Cruces J
FAU - Sanchez, A
AU  - Sanchez A
FAU - Massa, M J
AU  - Massa MJ
FAU - Gonzalez-Quevedo, R
AU  - Gonzalez-Quevedo R
FAU - Torres, A J
AU  - Torres AJ
FAU - Balibrea, J L
AU  - Balibrea JL
FAU - Benito, M
AU  - Benito M
LA  - eng
SI  - GENBANK/AJ007330
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (DNA, Neoplasm)
RN  - 0 (Genetic Markers)
SB  - IM
MH  - Animals
MH  - Base Pairing
MH  - Base Sequence
MH  - Carcinoma, Non-Small-Cell Lung/*genetics/mortality/pathology/surgery
MH  - Chromosome Mapping
MH  - *Chromosomes, Human, Pair 6
MH  - Cricetinae
MH  - DNA, Neoplasm/*genetics
MH  - Female
MH  - *Gene Amplification
MH  - Genetic Markers
MH  - Humans
MH  - Hybrid Cells
MH  - Lung Neoplasms/*genetics/mortality/pathology/surgery
MH  - Male
MH  - Mice
MH  - Middle Aged
MH  - Molecular Sequence Data
MH  - Polymerase Chain Reaction/*methods
MH  - Predictive Value of Tests
MH  - Survival Analysis
MH  - Time Factors
EDAT- 1999/07/15 00:00
MHDA- 1999/07/15 00:01
CRDT- 1999/07/15 00:00
PHST- 1999/07/15 00:00 [pubmed]
PHST- 1999/07/15 00:01 [medline]
PHST- 1999/07/15 00:00 [entrez]
AID - 10.1002/(SICI)1097-0215(19990820)84:4<344::AID-IJC2>3.0.CO;2-D [pii]
AID - 10.1002/(sici)1097-0215(19990820)84:4<344::aid-ijc2>3.0.co;2-d [doi]
PST - ppublish
SO  - Int J Cancer. 1999 Aug 20;84(4):344-9. doi: 
      10.1002/(sici)1097-0215(19990820)84:4<344::aid-ijc2>3.0.co;2-d.